Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ARENEGYR; CNGRC peptide-TNF alpha conjugate; NGR-hTNF; NGR-TNFα; Tumour-homing-peptide-tumour-necrosis-factor-alpha-fusion-protein; Tumour-vasculature-targeted-tumour-necrosis-factor-alpha; Zafiride

Latest Information Update: 07 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scientific Institute San Raffaele
  • Developer AGC Biologics; European Organisation for Research and Treatment of Cancer; MolMed; Scientific Institute San Raffaele
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Capillary permeability modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Mesothelioma
  • Phase II Colorectal cancer; Liver cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Small cell lung cancer
  • No development reported Ovarian cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 07 Sep 2021 No development reported - Phase-II for Mesothelioma (First-line therapy) in Germany, Russia, Italy (IV)
  • 07 Sep 2021 No development reported - Phase-II for Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom, Italy (IV)
  • 07 Sep 2021 No development reported - Phase-II for Soft tissue sarcoma (Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom, France, Italy (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top